References
- Alizadeh A A, Eisen M B, Davis R E, Ma C, Lossos I S, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511
- Shipp M A, Ross K N, Tamayo P, Weng A P, Kutok J L, Aguiar R C, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68–74
- Phan R T, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004; 432: 635–639
- Phan R T, Saito M, Basso K, Niu H, Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol 2005; 6: 1054–1060
- Saito M, Phan R T, Morse H C, III, Pasqualucci L, Dalla-Favera R. Pathologic co-expression and physical interaction of c-Myc and Bcl-6 in B cell lymphomas. Blood (Suppl.) 2005; 106: 5A
- Klein U, Tu Y, Stolovitzky G A, Keller J L, Haddad J, Jr, Miljkovic V, et al. Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci USA 2003; 100: 2639–2644
- Hans C P, Weisenburger D D, Greiner T C, Gascoyne R D, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282
- Cattoretti G, Pasqualucci L, Ballon G, Tam W, Nandula S V, Shen Q, et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 2005; 7: 445–455
- Reljic R, Wagner S D, Peakman L J, Fearon D T. Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6. J Exp Med 2000; 192: 1841–1848
- Saez A I, Artiga M J, Romero C, Rodriguez S, Cigudosa J C, Perez-Rosado A, et al. Development of a real-time reverse transcription polymerase chain reaction assay for c-myc expression that allows the identification of a subset of c-myc+ diffuse large B-cell lymphoma. Lab Invest 2003; 83: 143–152
- Aref S, Fouda M, El-Dosoky E, Menessy A, Mabed M, Saleeb M, et al. c-Myc oncogene and Cdc25A cell activating phosphatase expression in non-Hodgkin's lymphoma. Hematology 2003; 8: 183–190
- Chang C C, Liu Y C, Cleveland R P, Perkins S L. Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas. Am J Clin Pathol 2000; 113: 512–518
- Frost M, Newell J, Lones M A, Tripp S R, Cairo M S, Perkins S L. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol 2004; 121: 384–392
- Hutchison R E, Finch C, Kepner J, Fuller C, Bowman P, Link M, et al. Burkitt lymphoma is immunophenotypically different from Burkitt-like lymphoma in young persons. Ann Oncol 2000; 11(Suppl 1)35–38